An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV ...

Jena-based German biotech InflaRx has announced the pricing of an underwritten public offering, raising approximately $30 ...

Robert F Kennedy Jr. has been confirmed as the new secretary of the Department of Health and Human Services (HHS) after a ...

US mRNA specialist Moderna presented its fourth quarter and annual financial results on Friday, along with its 2025 guidance.

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...

California, USA-based fibrosis specialist Pliant Therapeutics saw its shares leap 20.95% to $3.29 by close of trading ...

A new report from industry trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has shed a new light ...

Swiss biotech Oculis Holding yesterday announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.00 per share, for ...

Italian pharma major Recordati has reported strong preliminary consolidated financial results for 2024, with the firm’s shares edging up 2.3% to 60.40 euros.

US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...